DCTs were proclaimed as the silver bullet during the pandemic, but it is now clear that they are not as cheap or easy as expected.

The 5th Optimizing Hybrid Clinical Trials Summit is uniting stakeholders in Clinical Operations, Innovation, Procurement and Digital Health and more to share practical case studies in building a budget and financial business case to run DCTs, securing end-to-end data flow, and managing data integrity and quality to operationalize hybrid trials.

With practical insight into building a compelling financial case to run hybrid trials, enhancing data quality and integrity with electronic data capture systems and employing digital solutions to reduce patient burden, join 80+ senior stakeholders including Pfizer, Bayer, Eli Lilly & Co, Astellas, UCB, AbbVie and more to explore strategies to optimize hybrid clinical trials and enhance DE&I and patient access, improve operational efficiency and leverage remote data collection to demonstrate efficacy and safety in DCTs.